Evidence map›Paper›PMID 31366929›Full record

ArticleNature communications2019

Publisher Correction: IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function.

Chiara Montemurro, Hiroshi Nomoto, Lina Pei, Vishal S Parekh, Kenny E Vongbunyong, Suryakiran Vadrevu, Tatyana Gurlo, Alexandra E Butler, Rohan Subramaniam, Eleni Ritou and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Chiara MontemurroLarry L. Hillblom Islet Research Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90024, USA.ORCID http://orcid.org/0000-0002-7070-2724
Hiroshi NomotoLarry L. Hillblom Islet Research Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90024, USA.ORCID http://orcid.org/0000-0003-0713-221X
Lina PeiLarry L. Hillblom Islet Research Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90024, USA.
Vishal S ParekhDepartment of Pharmacology and Brehm Diabetes Research Center, University of Michigan, Ann Arbor, MI, 48105, USA.
Kenny E VongbunyongLarry L. Hillblom Islet Research Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90024, USA.
Suryakiran VadrevuDepartment of Pharmacology and Brehm Diabetes Research Center, University of Michigan, Ann Arbor, MI, 48105, USA.
Tatyana GurloLarry L. Hillblom Islet Research Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90024, USA.
Alexandra E ButlerLarry L. Hillblom Islet Research Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90024, USA.
Rohan SubramaniamLarry L. Hillblom Islet Research Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90024, USA.
Eleni RitouDivision of Endocrinology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90024, USA.
Orian S ShirihaiDivision of Endocrinology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90024, USA.
Leslie S SatinDepartment of Pharmacology and Brehm Diabetes Research Center, University of Michigan, Ann Arbor, MI, 48105, USA.
Peter C ButlerLarry L. Hillblom Islet Research Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90024, USA.
Slavica TudzarovaLarry L. Hillblom Islet Research Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90024, USA. STudzarova@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-9617-3779

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
NIDDK NIH HHS P30 DK041301
6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID31366929
PMCPMC6668385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.